Deep Dive Ticker Tape
Article published Mar 11, 2026. Prices below use latest available snapshots.
IQV Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium Status: FRESH DATA — RSI 39.4, price $170.93, recovering from extreme oversold, near SMA
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 RSI 39.4 (computed, FRESH) — approaching neutral from oversold. Price $170.93, -4.3% today, -3.1% 7D, -3.5% 30D. SMA20 ~$171.65 — price -0.4% below SMA. |
| Moat | Wide (1B+ patient records, 90% of top pharma) |
| Key insight | IQV data is now FRESH after 15+ days stale. The real picture is much better than feared: RSI recovered from 17.4 to 39.4 — a significant improvement. Price rose from $162.31 (stale) to $170.93 (+5.3%). Price is now right at SMA ($171.65). The wide moat thesis is intact. -4.3% today suggests some selling pressure but the recovery from RSI 17 is confirmed. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | 🔍 Watch / Approaching Accumulate | RSI recovered to 39; near SMA. Wait for stabilization above $170. |
| Entry Zone | $160 - $175 | Current $170.93 — IN ZONE |
| Stop-Loss | $134 (-22%) | Below April 2025 52-week low |
| Target | $217 (+27%) | Return to 3-month mean |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| IQV | $170.93 | -4.3% | -3.1% | -3.5% | -24.4% | 39 | 🟡 Approaching Neutral | 🔍 Watch |
Price vs Last Deep Dive (03/10 stale)
| Metric | 03/10 (stale) | 03/11 (fresh) | Change |
|---|---|---|---|
| Price | $162.31 (stale) | $170.93 | +$8.62 (+5.3%) |
| RSI | 17.4 (stale) | 39.4 | +22.0 (major recovery) |
| SMA20 | $195.64 | ~$171.65 | SMA declined to meet price |
Update from 03/10: CRITICAL — IQV data is now FRESH. The extended RSI 17 reading was stale. Real RSI is 39.4 — the stock recovered significantly. Price at $170.93 is right at SMA. The failed recovery pattern (RSI 14 → 25 → 17) appears to have resolved. Still need to watch for stabilization above SMA before committing.
Company Overview
One-Liner
IQVIA provides data analytics, technology solutions, and contract research services to the life sciences industry.
Competitive Moat
| Moat Type | Present? | Evidence |
|---|---|---|
| Network effects | 🟢 | More data from trials = better analytics |
| Switching costs | 🟢 | Multi-year contracts, deeply embedded platforms |
| Cost advantages | 🟢 | Scale across 100+ countries |
| Intangible assets | 🟢 | Proprietary datasets covering 1B+ patient records |
Moat Width: Wide
Bull Case
- Wide moat confirmed — 1B+ patient records, 90% of top pharma.
- RSI recovery 17 → 39 — Bottom formation confirmed.
- P/E ~13x forward vs 5Y avg ~25x — Near valuation floor.
- Price at SMA — Convergence point.
Bear Case
- -4.3% today — Still experiencing selling pressure.
- 3M -24.4% — Significant distance from highs.
- R&DS cancellation trend — CRO pipeline concerns.
- $13B debt — Refinancing cost risk.
Research Log
| Date | Update |
|---|---|
| 2026-02-15 | Created. RSI 14 extreme. $162.31. Wide moat, fair value $210-$230. |
| 2026-02-22 | $165.62. RSI improved to 25.5 — stabilization. |
| 2026-02-26 | $162.31. RSI slipped to 17.4 (failed recovery). |
| 2026-03-03 | OHLC stale. No entry signal. |
| 2026-03-10 | OHLC still stale (15+ days). |
| 2026-03-11 | FRESH DATA. $170.93. RSI 39.4 (computed). Major recovery from 17.4. At SMA. Watch for stabilization. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| RSI 17 → 39 recovery confirmed with fresh data | Bottom formation validated — the failed recovery resolved |
| Price at SMA convergence | Critical inflection — hold above SMA = bullish; fail = bearish |
| Stale data masked real recovery | Always fetch before updating |
Open Questions
- Has the Feb 12 low ($156.67) held? (Appears yes — $170 now)
- Is R&DS cancellation trend worsening?
- What is the refinancing schedule for $13B debt?